UroGen Pharma to Participate in the B. Riley Healthcare Conference
January 11 2024 - 8:00AM
Business Wire
- Fireside Chat January 18, 2024, at 12:00 pm
ET -
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that Liz Barrett,
President and CEO, will participate in a fireside chat at the
upcoming B. Riley Virtual Healthcare Conference on January 18th
beginning at 12:00 p.m. ET.
To access the event, please RSVP to your B. Riley Securities
sales representative. Following the event, a replay of the fireside
chat will be available at the "Events and Presentations" section of
UroGen’s investor website for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Jelmyto®
(mitomycin) for pyelocaliceal solution and investigational
treatment UGN-102 (mitomycin) for intravesical solution are
designed to ablate tumors by non-surgical means. UroGen is
headquartered in Princeton, NJ with operations in Israel. Visit
www.urogen.com to learn more or follow us on Twitter,
@UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111451437/en/
INVESTOR CONTACT: Vincent Perrone Senior Director,
Investor Relations vincent.perrone@urogen.com 609-460-3588
MEDIA CONTACT: Cindy Romano Director, Communications
cindy.romano@urogen.com 908-963-7827
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From Apr 2024 to May 2024
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From May 2023 to May 2024